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DNA methylation is recognized as the most im-
portant epigenetic change in the malignant transfor-
mation. It includes global hypermethylation and the 
hypermethylation of CpG islands localized in the regu-
latory regions of most human genes [1, 2]. Methylated 
cytosine may undergo spontaneous deamination, pro-
ducing a C → T transition, which, if in the promoter, may 
significantly affect the level of expression of a gene and 
eventually lead to its silencing. Methylated sequences 
in DNA are also targeted by specific proteins, which 
can recruit chromatin remodeling proteins changing 
the accessibility of a gene for transcription machinery 
and, again, affecting the level of its expression. 
An aberrant methylation in cancer-related genes is 
frequently detected in materials from gastric tumors, 
suggesting its involvement in the induction/promotion 
of gastric cancer [3–5]. The identification of methy-
lated genes may provide an insight in the molecular 
mechanisms of tumor development and might reveal 
new tools to define markers of prognostic significance. 
In addition, identification of hypermethylated genes 
may be useful in cancer therapy, by more specific 
targeting cancer cells on the basis of their methyla-
tion status. To investigate the methylation pattern in 
gastric cancer we examined the methylation of the pro-
moter of 8 tumor-suppressor genes: Apaf-1, Casp8, 
CDH1, MDR1, GSTP1, BRCA1, hMLH1 and Fas. The 
products of these genes may protect the genome 
from mutagenesis (hMLH1, BRCA1, GSTP1, MDR1), 
impede deregulated progression through the cell cycle 
(BRCA1), induce apoptosis in cells that escape normal 
cell cycle controls (Apaf-1, Casp8, Fas), and inhibit 
cellular migration and metastasis (CDH1) [6]. 
The human Apaf-1 gene encodes a cytoplasmic 
protein involved in the mitochondrial apoptosis path-
way [7]. The gene may be closely related to some proto-
oncogenes and tumor suppressor genes, including 
p53 and Bcl-2 [8, 9]. The lowered expression of Apaf-1 
gene or its inactivation was associated with methylation 
silencing in acute leukemia and laryngeal squamous 
carcinoma [10, 11]. The caspase 8 protein encoded by 
Casp8 gene plays also a major role in the process of 
apoptosis [7]. Because many anticancer drugs induce 
apoptosis by the activation of the caspase cascade, 
the deactivation of this pathway by silencing of Casp8 
may lead to drug-resistance of cancer cells. The protein 
encoded by the Fas gene is a member of the family 
of death receptors that induce apoptosis in sensitive 
cells upon binding to their specific death ligands [12]. 
Silencing of the Fas receptor by DNA methylation was 
reported in several cancers [13]. The CDH1 gene en-
codes E-cadherin, a protein involved in cellular adhe-
sion, tumor growth, invasion and metastasis [4, 14]. 
The hMLH1 gene encodes the DNA mismatch protein 
MLH1, playing a role in familial colorectal cancer and in 
sporadic gastric carcinomas that display microsatellite 
instability phenotype [3, 5, 15, 16]. BRCA1 is a breast 
cancer susceptibility protein, playing an essential role 
in the repair of DNA double strand breaks [17, 18]. The 
MDR1 gene codes for glycoprotein P, involved in cellular 
transport and its aberrant expression can be important 
for etiology and progression of various cancers [19]. 
GSTP1 is an enzyme, important for the detoxification 
of mutagens/carcinogens [20, 21]. 
In the present work we have also checked the asso-
ciation between the hypermethylation of and age, gen-
der, smoking and family history of gastric cancer.
MATERIALS AND METHODS
Tissue samples. Tissue samples were taken from 
27 patients with gastric cancer during gastrectomy 
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performed in 2006 and 2007 in the Nicolas Copernicus 
Hospital, Lodz, Poland. The patients did not undergo 
chemotherapy. Blood samples from age-matched 
healthy individuals, who had no current or previous 
diagnosis of cancer, were obtained from 25 patients 
of Polish Mother’s Memorial Institute, Lodz, Poland 
and Community Health Centre, Rzgow, Poland. A local 
ethic committee approved the study and each patient 
enrolled gave a written consent. 
Chemicals. The genomic DNA from gastric 
tumors and lymphocytes of peripheral blood was 
isolated with GeneMATRIX Blood DNA Purification Kit 
and  GeneMATRIX Tissue DNA Purification Kit (EurX, 
Gdansk, Poland) respectively. Methylation-specific 
restriction enzyme Hin6I was obtained from Fermentas 
(Abo, Gdansk, Poland). All reagents for PCR reaction 
were from Qiagen (GmbH, Hilden, Germany). Electro-
phoresis was conducted in TAE buffer.
Methylation specific restriction enzyme diges-
tion PCR. The assessment of methylation status was 
conducted by methylation specific restriction enzyme 
digestion PCR (MSRE-PCR) [22]. Digestion of ge-
nomic DNA was preformed with methylation-specific 
enzyme Hin6I. The enzyme recognizes and digests 
the unmethylated 5’-GCGC-3’ sequence, whereas its 
methylated variant is left intact. 150 ng of genomic DNA 
was mixed with 100 pg of pUC19 plasmid and digested 
with 40 U of the enzyme in 37 °C for 72 h in a total volu-
me of 50 ml and PCR reaction was run. The fragments 
of the promoters of the gene under study contained 
at least one, but no more than nine, Hin6I recognition 
sites located in CpG islands were selected for amplifi-
cation. The sequences of primers are given in Table 1. 
After digestion with the enzyme, a PCR reaction with 
primers specific to a 457 bp fragment of pUC19 was 
performed. The primers flanked a region containing 
four Hin6I recognition sites. Results of this reaction 
served as a quality control of the digestion. Next, a 
separate PCR reaction was conducted for each gene. 
In three of examined genes (Apaf-1, CDH1, GSTP1) 
the standard PCR reaction mix was enriched by Q-
Solution buffer (Qiagen, GmbH, Hilden, Germany). 
The thermocycler was programmed for 35-cycles with 
annealing temperature 60 °C (except for CDH1, where 
it was 65 °C). Control samples with non-digested DNA 
were included for each PCR reaction to ensure that a 
lack of the product in digested samples was a result 
of enzymatic degradation of unmethylated template, 
and not of the PCR reaction failure. Only those samples 
which yielded products in undigested control where 
taken for further analysis.
Statistical analysis. Differences between groups 
were examined using Fisher’s exact test and those at 
p < 0.05 were considered significant. The statistical 
analysis was preformed using STATISTICA 6.0 package 
from StatSoft (Tulsa, OK, USA).
RESULTS
We determined the status of the promoter methy-
lation of the Apaf-1, Casp8, CDH1, MDR1, GSTP1, 
BRCA1, hMLH1 and Fas genes in 27 gastric cancer 
patients and 25 healthy individuals. Two of the genes, 
Apaf-1 and Fas, were unmethylated in both gastric 
cancer patients and the controls. Four of eight genes 
were more frequently methylated in gastric cancer 
patients than in the control (Casp8 81% vs 0%, MDR1 
100% vs 28%, hMLH1 22% vs 0% and CDH1 74.1% 
vs 28%). These results are presented in Table 2. It has 
been recently reported that concurrent hypermethyla-
tion of multiple tumor-related genes, including hMLH1, 
is detected frequently in various carcinomas. It was 
suggested that silencing of hMLH1 led to changes in 
CpG-island methylation pattern and resulting silencing 
of other genes may contribute to neoplastic transfor-
mation [23, 24]. We did not find statistically significant 
differences between groups in concurrent methylation 
of hMLH1 and two or more other methylated genes 
(Table 3). We also analyzed the methylation changes 
in the gastric cancer tissue and the questionnaire data 
obtained from the patients (Table 4). The promoter 
hypermethylation of GSTP1 and hMLH1 were more 
frequent in female than in male (100% vs 5.26% for 
GSTP1 and 71.43% vs 5.26% for hMLH1). When we 
compared the methylation in smoking and nonsmoking 
groups, we found a statistically relevant difference for 
CDH1 (100% vs 66.67%). We did not find any correla-
tion between promoter hypermethylation and age and 
gastric cancer family history. 
Table 2. The frequency of DNA hypermethylation in gastric cancer and 
control group
Frequency of hypermethylation (%)
Casp 8 Apaf-1 MDR1 GSTP1 BRCA1 hMLH1 Fas CDH1
Cases 81* 0 100* 3.7 3.7 22** 0 74.1**
Control 0 0 28 0 0 0 0 28
*p < 0.001; **p < 0.05.
Table 3. Concurrent hypermethylation of the hMLH1 gene with other 
genes
hMLH1 Concurrent hypermethylation (> 1 genes)
Methylated 6 6 (100%)
Unmethylated 21 18 (85%)
DISCUSSION
We demonstrated that DNA hypermethylation at 
the promoter regions of the Casp8, hMLH1, CDH1 and 
MDR1 genes occur more frequently in gastric cancer 
than in normal tissue. The loss of Casp8 expression in 
Table 1. Sequences of primers used in MSRE-PCR
Gene Forward primer (5’ to 3’) Reverse primer (5’ to 3’) Product length
Apaf-1 GCGCCTTCCACTGCGATATTGC TTCCCACCAATGCCGGACTC 154 bp
Casp8 CCATCTGGTAGATACCAGGCATGA TGAGCTCCAAGTCCACTCTGTT 443 bp
CDH1 CAAGGCAGGAGGATCGCTTCAG CTGACTTCCGCAAGCTCACAGG 658 bp
MDR1 AGAGGTGCAACGGAAGCCAGAAC GCTTGGAAGAGCCGCTACTCGAATG 218 bp
GSTP1 TCCGGGATCGCAGCGGTCTTAGG TCTTCTGGAGGGTCCCGCGGACT 262 bp
BRCA1 TGAGAGGCTGCTGCTTAGCGGTAG AAATCCACTCTCCCACGCCAGTACCC 266 bp
hMLH1 CGCCACATACCGCTCGTAGTATTC GCTGTCCGCTCTTCCTATTGGTTC 419 bp
Fas CGTCTGTGAGCCTCTCATGT CTCCAGCCAAGTCACTCGTA 523 bp
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cancer cells may result in resistance to drug-induced 
apoptosis, and may be important for therapeutic 
strategy [25–27]. Recent studies demonstrated that 
demethylation of CpG islands of Casp8 gene in resis-
tant cancer cells sensitized them to chemotherapeutic 
agents [28, 29]. Moreover, inactivation of Casp8 ex-
pression by promoter hypermethylation may result in 
cancer progression. Casp8 methylation was detected 
in 90% of medulloblastoma samples by nonquantita-
tive methylation-specific PCR. Cancer progression and 
invasion can be also correlated with the loss of CDH1 
expression. Recent data indicate that E-cadherin level 
is decreased in wide spectrum of tumors, including 
head and neck, breast and gastric cancer, and that 
this event correlates with DNA methylation in CDH1 
promoter region [4, 14, 30]. Methylation of CDH1 
promoter in gastric cancer occurs in early steps of 
carcinogenesis and may be initiated by H. pylori 
infection, which colonizes gastric mucosa cells and 
introduces many cytotoxic agents which may act as 
hypermethylating agents [31, 32].
Table 4. Association between the characteristics of the subject and promoter 
hypermethylation
Variables Frequency of hypermethylation (%)Casp 8 MDR1 GSTP1 BRCA1 hMLH1 CDH1
Sex
Female 100 100 100* 14.29 71.43* 85.71
Male 73.68 100 5.26 0.00 5.26 73.68
Age
< 60 91.67 100 8.33 0 18.18 90.91
> 60 71.43 100 0 7.14 28.57 71.43
Smoking
Yes 87.5 100 0 0 25.00 100*
No 77.78 100 5.56 5.56 22.22 66.67
Family history**
Yes 66.67 100 16.67 0 0 66.67
No 85.00 100 0 5.00 30.00 80.00
*p values < 0.05; **one or more first-degree relatives with gastric cancer.
The role of the MDR1 gene in carcinogenesis is 
rather controversial. The lack of its expression was re-
ported in prostate cancer [33] and seems to contribute 
to the progression of neuroblastoma [34]. Other re-
ports correlate MDR1 expression with cancer initiation 
and progression rather than the gene silencing [35]. 
The correlation reported in our study between gastric 
cancer and DNA methylation of the MDR1 promoter 
needs further studies performed on a larger group.
Previous reports suggest that there is a concur-
rent hypermethylation of multiple genes in neo-
plastic diseases, including acute myeloid leukemia, 
colorectal, pancreatic, lung and gastric carcinoma 
[14, 24, 36–39]. Tumors with concurrent methyla-
tion in multiple loci have been called the CpG-island 
methylator phenotype. The presence of concurrent 
hypermethylation may imply a mechanism leading to 
aberrant methylation of CpG-island that contributes 
to cancer development. We tried to compare the 
hypermethylation pattern between hMLH1 and other 
genes used in this study. We showed that concurrent 
hypermethylation of hMLH1 and other genes was a 
common event in gastric cancer. Unfortunately we do 
not have data on the microsatellite instability status of 
studied cases of gastric carcinoma. Thus, more de-
tailed studies performed on a larger group with more 
detailed characteristics are needed to establish an 
association between concurrent hypermethylation of 
hMLH1 and other genes.
We also investigated an association between pro-
moter hypermethylation and age, gender, smoking 
and family history. We found that hypermethylation of 
GSTP1 and hMLH1 promoter region was more com-
mon in women than in men. Our data suggest that 
some genes show gender specific pattern, what is 
in agreement with other reports [40]. The explana-
tion for this fact remains unknown. Previous studies 
showed that the number of methylated gene promo-
ters increased with age [41, 42]. We did not confirm 
these data but a limitation of our study is the number 
of analyzed cases. The study performed on a larger 
group should establish the correlation between DNA 
hypermethylation, aging and cancer. We also exami-
ned correlation between promoter hypermethylation 
and smoking. The proportion of promoter methylation 
of CDH1 gene was significantly increased in smoking 
group. Our data are consistent with previous results 
suggesting that DNA hypermethylation pattern may 
be influenced by smoking [42].
In conclusion, our study regarding promoter 
hypermethylation of tumor-related genes in gastric 
cancer showed the high frequency of methylation of 
the Casp8, MDR1, CDH1 and hMLH1 genes. This study 
also demonstrated that aberrant DNA methylation can 
be associated with female gender and smoking. 
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МЕТИЛИРОВАНИЕ ПРОМОТОРОВ 
ОПУХОЛьАССОЦИИРОВАННЫХ ГЕНОВ ПРИ РАКЕ ЖЕЛУДКА
Генетические изменения, ассоциированные с опухолью желудка, изучены не в полной мере. В то же время эпигенетические 
механизмы скорее всего играют ключевую роль и лежат в основе возникновения этого за�олевания. �дин из таких механиз-
мов – нарушения метилирования промоторов генов, которые регулируют злокачественную трансформацию и прогрессирование 
опухолевого процесса, может �ыть осо�енно важным в развитии рака желудка. Цель: проанализировать статус метилирования 
промоторов восьми генов: Apaf-1, Casp8, CDH1, MDR1, GSTP1, BRCA1, hMLH1, Fas у �ольных раком желудка. Методы: ме-
тилирование промоторов генов изучали с помощью специфической к сайтам метилирования рестрикцией с ПЦР (MSRE-PCR) 
на хирургическом материале (опухоли желудка) 27 пациентов. В качестве контроля использовали �иопсийный материал, полу-
ченный от 25 �ольных, у которых не �ыло выявлено рака или предраковых состояний. Результаты: отмечали гиперметилиро-
вание промоторов генов Casp8, hMLH1, CDH1 и MDR1 в опухолевой ткани желудка по сравнению с контрольными о�разцами. 
Кроме того, нами �ыла прослежена взаимосвязь между гиперметилированием промоторов генов и возрастом, полом пациентов, 
курением и семейной историей за�олевания раком желудка. Гиперметилирование гена hMLH1 выявляли чаще у женщин, чем у 
мужчин, а гиперметилирование гена CDH1 — в основном у курильщиков. Выводы: полученные данные свидетельствуют о том, 
что метилирование ДНК может играть важную роль при развитии рака желудка. 
Ключевые слова: гиперметилирование ДНК, рак желудка, опухольассоциированные гены, MRSE-PCR.
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